m
Recent Posts
Connect with:
Monday / November 16.
HomeminewsInternational Study Positive on SightScore Genetic Glaucoma Testing

International Study Positive on SightScore Genetic Glaucoma Testing

New research published in Ophthalmology,1,2 reports that the polygenic risk score (PRS) underlying Seonix Bio’s SightScore test can help identify people at substantially different levels of risk for developing glaucoma – and may also help predict disease progression and the likelihood of surgery.

SightScore uses a saliva test to identify individuals at high risk for glaucoma. Developed using genetic data from more than 6.5 million individuals, SightScore’s PRS was evaluated across independent cohorts representing major ancestry groups. The findings suggest that genetic risk information, used alongside clinical assessments, could help clinicians identify higher-risk patients earlier and better tailor monitoring and treatment decisions. 

The international study found that across three validation datasets, people in the highest 10% of genetic risk had approximately 100 times the odds of glaucoma compared with those in the lowest 10%. 

In a population-based analysis, the highest-risk group reached a 3% glaucoma prevalence more than 25 years earlier than the lowest-risk group. The PRS showed predictive value across European, African, East Asian, South Asian, and Latino ancestry groups. In a US African American cohort, those with the highest 10% of genetic risk had 3.8 times the odds of glaucoma compared with the remainder of the cohort. 

“enhanced PRS… enables effective risk stratification for OAG across diverse ancestries, facilitating earlier identification and treatment of high-risk individuals while supporting resource rationalisation for those at low risk” 

The research found that adding the PRS to models that included age, sex and eye pressure improved glaucoma prediction in US-, European-, Latino- and African-ancestry cohorts. 

The study also examined longitudinal clinical outcomes in people with suspected or early-stage glaucoma. In a prospective cohort of 1,215 participants, 24% of those in the highest PRS decile had undergone glaucoma surgery by age 80, compared with none in the lowest decile. Higher PRS was also associated with retinal nerve fibre layer loss and an increased likelihood of treatment initiation or escalation within three years. 

The authors concluded that the “enhanced PRS, available for clinical use through an accredited genotyping workflow, enables effective risk stratification for OAG [open-angle glaucoma] across diverse ancestries, facilitating earlier identification and treatment of high-risk individuals while supporting resource rationalisation for those at low risk.”2 

They observed that performance was strongest in European-ancestry populations, and stated that further work is needed to improve equity of performance across ancestries. 

Complementing Clinical Judgement 

In a statement, Seonix Bio said the PRS is intended to complement, not replace, clinical judgment and established assessments. It said findings from the published study point to a role for genetic testing in identifying patients who may warrant closer monitoring or earlier specialist evaluation, while helping clinicians consider less intensive surveillance for lower-risk patients.1  

“Glaucoma care has traditionally relied on clinical measurements that may not fully capture a patient’s inherited risk or predict future disease course,” said Nick Haan, CEO of Seonix Bio. “This research shows the potential of genetic information to add a meaningful dimension to risk assessment, not only helping identify who may develop glaucoma, but also providing insight into who may be more likely to progress and require surgery. Our goal is to make this information useful to clinicians as they work to protect patients’ vision.” 

Dr Iqbal ‘Ike’ K. Ahmed, Professor of Ophthalmology at the University of Utah’s John A. Moran Eye Center and Director of the Alan S. Crandall Center for Glaucoma Innovation, said determining which glaucoma patients are most likely to progress and who may benefit from intervention is a “persistent challenge”. 

“These findings are notable because they connect genetic risk not only with disease susceptibility, but also with progression and the likelihood of surgery. Polygenic risk scores increasingly provide important risk information, invisible to conventional testing, that can help clinicians move glaucoma care toward more individualised decisions,” he added.

Reference 

  1. Seonix Bio. New research shows SightScore can help predict glaucoma risk, progression and surgery. Available at seonixbio.com/news/new-research-shows-sightscore-can-help-predict-glaucoma-risk-progression-and-surgery [accessed Nov 2026].
  2. 2. MacGregor S, Ni G, Seviiri M, et al. Step change in glaucoma polygenic risk score performance enables clinical utility. Opthalmology. Published online 2026. doi:10.1016/j.ophtha.2026.00788-8. 

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.